Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
A phase 3 clinical trial compared two antibiotics, ceftobiprole and daptomycin, as treatments for complicated Staphylococcus aureus bacteremia. Patients were randomly assigned to receive either ceftobiprole or daptomycin, and the primary outcome measured success in treatment after 70 days. Both antibiotics showed similar results in terms of overall treatment success, mortality, and microbiologic eradication. Adverse events were reported in both groups, with more gastrointestinal issues reported in the ceftobiprole group. In conclusion, ceftobiprole was found to be as effective as daptomycin for treating complicated Staphylococcus aureus bacteremia.